A Study of Oral Etoposide, Infusional Cisplatin, and Infusional 5‐Fluorouracil for Locally Advanced or Metastatic Non‐Small-Cell Lung Cancer: A Mid‐Atlantic Oncology Program Study
A Study of Oral Etoposide, Infusional Cisplatin, and Infusional 5‐Fluorouracil for Locally Advanced or Metastatic Non‐Small-Cell Lung Cancer: A Mid‐Atlantic Oncology Program Study
复制标题
口服依托泊苷、输注顺铂和输注 5-氟尿嘧啶治疗局部晚期或转移性非小细胞肺癌的研究：中大西洋肿瘤学计划研究
DOI：
--
复制
发表时间：
1992
期刊：
影响因子：
--
通讯作者：
Diane E. Alt
中科院分区：
文献类型：
--
作者：
C. J. Rosenthal;G. Wampler;H. Brereton;J. Ahlgren;J. Lokich;J. Fryer;Diane E. Alt
在一项 II 期试验中，口服依托泊苷、输注顺铂（24 小时）和输注 5-氟尿嘧啶（5 天）的组合用于治疗 87 名非小细胞肺癌患者。 26 名患者为 IIIB 期，61 名患者为 IV 期（新的国际分类）。该方案耐受性良好，所有类型的 3 级或 4 级毒性均为 49%。 IV 期患者的部分和完全缓解率为 40%（95% 置信区间：30%、51%），IIIB 期患者的部分和完全缓解率为 20%（95% 置信区间：10%、32%）。另外 68% 的 IIIB 期患者和 45% 的 IV 期患者病情稳定，中位生存期为 8.8 个月，与部分缓解的患者相似。 IV 期患者的中位生存期为 5.6 个月（95% 置信区间：4.4 个月、10.8 个月），IIIB 期患者的中位生存期为 11.0 个月（95% 置信区间：8.8 个月、12.4 个月）。有趣的是，症状持续时间较短的患者（>6 个月与 ≤6 个月）的缓解率较高。
A combination of oral etoposide, infusional cisplatin (24-hr) and infusional 5-fluorouracil (5-day) was used to treat 87 patients with non-small-cell lung cancer in a Phase II trial. Twenty-six patients were Stage IIIB, and 61 patients were Stage IV (new international classification). The regimen was well tolerated, with 49% grade 3 or 4 toxicities of all types. Response rates, partial and complete, were 40%, (95% confidence interval: 30%, 51%) for Stage IV patients and 20% (95% confidence interval: 10%, 32%), in Stage IIIB. An additional 68% of patients in Stage IIIB and 45% of patients in Stage IV achieved stable disease and had a median survival of 8.8 months, similar to that of patients in partial remission. Median survival was 5.6 months (95% confidence interval: 4.4 months, 10.8 months) for Stage IV patients and 11.0 months (95% confidence interval: 8.8 months, 12.4 months), for Stage IIIB. Of interest was the finding of a higher response rate in patients with a shorter duration of symptoms (>6 months versus ≤6 months).